Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom
详细信息 查看全文
- 作者：Barnaby Hunt ; Qing Ye ; William J. Valentine ; Donna Ashley
- 关键词：Cost ; Cost ; effectiveness ; Diabetes mellitus ; Exenatide ; GLP ; 1 receptor agonist ; Liraglutide ; Lixisenatide
- 刊名：Diabetes Therapy
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：8
- 期：1
- 页码：129-147
- 全文大小：657KB
- 刊物主题：Internal Medicine; Diabetes; Cardiology; Endocrinology;
- 出版者：Springer Healthcare
- ISSN：1869-6961
- 卷排序：8
文摘
IntroductionThe glucagon-like peptide-1 (GLP-1) receptor agonist class has grown in the last decade, with several agents available in the UK. However there is currently a paucity of evidence regarding the relative cost-effectiveness of liraglutide 1.2 mg versus other daily administered GLP-1 receptor agonists, due to a lack of head-to-head trial data. Therefore the present analysis was performed, using results from a network meta-analysis (NMA), to compare the cost-effectiveness of three currently available daily administered GLP-1 receptor agonists for treatment of diabetes in the UK setting.